Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

823.96
-5.8038-0.70%
Volume:2.25M
Turnover:1.85B
Market Cap:781.25B
PE:70.36
High:830.92
Open:825.99
Low:811.64
Close:829.76
Loading ...

Olix Pharmaceuticals Inc - to Receive Initial Payment From Lilly to Complete Phase 1 Trial

THOMSON REUTERS
·
10 Feb

Eli Lilly and Company (LLY): Among Ken Fisher’s Top High Growth Stock Picks

Insider Monkey
·
09 Feb

Is Eli Lilly and Company (LLY) the Best Stock to Invest In for Grandchildren?

Insider Monkey
·
08 Feb

Major Eli Lilly Shareholder Sells Massive Stock Holding

TIPRANKS
·
08 Feb

Sector Update: Health Care Stocks Lower Friday Afternoon

MT Newswires Live
·
08 Feb

Leerink Partners Adjusts Eli Lilly and Company's Price Target to $989 From $950

MT Newswires Live
·
08 Feb

Eli Lilly price target raised to $1,000 from $997 at BofA

TIPRANKS
·
07 Feb

Eli Lilly Reports Sustained Clinical Remission, Endoscopic Response in Patients With Crohn's Disease Treated With Omvoh

MT Newswires Live
·
07 Feb

BUZZ-Street View: Eli Lilly's drug pipeline to aid growth

Reuters
·
07 Feb

Eli Lilly & Co: Buy Rating Affirmed on Strong Pipeline and Strategic Growth Initiatives

TIPRANKS
·
07 Feb

BRIEF-Eli Lilly Says Most Patients On Omvoh® For Crohn's Disease Achieved Remission And Endoscopic Response At Two Years

Reuters
·
07 Feb

Eli Lilly Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
07 Feb

Eli Lilly announces results from VIVID-2 study

TIPRANKS
·
07 Feb

Most Patients on Lilly's Omvoh® (Mirikizumab-Mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two Years

THOMSON REUTERS
·
07 Feb

Eli Lilly and Co - Nearly 90% of Patients Sustain Endoscopic Response at Two Years

THOMSON REUTERS
·
07 Feb

Citi Keeps Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
07 Feb